Among patients with newly diagnosed advanced non-small cell lung cancer (NSCLC) with high tumour mutational burden (TMB, >10 mutations/Mb), those who received nivolumab plus ipilimumab had significantly improved progression-free survival (PFS) compared...
Original Article: AACR 2018: CheckMate-227 meets co-primary endpoint of PFS in NSCLC